Editor's note: An earlier version of this article incorrectly stated that Eli Lilly purchased two companies from Siemens. The actual transaction was for two tracers used in detecting tau tangles. The video also misidentifies a collaboration between Eli Lilly and General Electric for similar diagnostic products. GE Healthcare is developing a tau tangle imaging test that is independent of Eli Lilly. The Fool regrets the error.
In this video, health care analyst David Williamson discusses Eli Lilly's (NYSE: LLY ) recent purchase of two imaging tracers from German conglomerate Siemens. The big pharma currently has Amyvid approved, which detects amyloid brain plaques. Like Amyvid, Eli Lilly is hoping that these tau tangle diagnostics will help both with detection and potentially serve as markers for treatment. Watch and find out how the treatment for Alzheimer's disease is evolving and some potentially groundbreaking drugs in the pipeline.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more, click here to claim your copy today.